SCHEMBL1744659

SCHEMBL1744659

COC(=O)CCc1ccc2oc(-c3ccc(OC)cc3)cc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.62
FFAR1 O14842 8/20 0.57
MAOB P27338 2/20 0.55
APP P05067 3/20 0.52
PTGES O14684 1/20 0.50
ALOX5 P09917 1/20 0.50
CYP2C8 P10632 1/20 0.48
TP53 P04637 3/20 0.47
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
CYP3A4 P08684 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
ALDH1A1 P00352 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747131 0.89 FFAR1 (0.73) MAOAFFAR1MAOBAPPPTGES
SCHEMBL1745150 0.87 FFAR1 (0.64) MAOAFFAR1MAOBPTGESALOX5
SCHEMBL3003302 0.86 CYP2C8 (0.67) MAOAFFAR1MAOBALOX5CYP2C8
SCHEMBL3001663 0.84 CYP2C8 (0.55) FFAR1PTGESALOX5CYP2C8MAPT
SCHEMBL3006301 0.82 CYP2C8 (0.58) MAOAFFAR1CYP2C8MAPTKDM4E
SCHEMBL29214227 0.81 MAOA (0.61) MAOAFFAR1MAOBAPPPTGES
SCHEMBL30861765 0.81 MAOA (0.61) MAOAFFAR1MAOBAPPPTGES
SCHEMBL1747073 0.81 MAOA (0.44) MAOAMAOBTP53MAPTKDM4E
SCHEMBL29214152 0.78 APP (0.59) MAOAMAOBAPPPTGESALOX5
SCHEMBL5593706 0.78 MAPT (0.74) MAOATP53MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MAOA 4245/4885FFAR1 33/4885MAOB 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.